On July 21, 2025, Nuvalent, Inc. reported the initiation of ALKAZAR, its Phase 3 clinical trial evaluating neladalkib for TKI-naïve patients with advanced ALK-positive non-small cell lung cancer, versus ALECENSA, a front-line standard of care, with the dosing of the first patient in the trial (Press release, Nuvalent, JUL 21, 2025, View Source [SID1234654453]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!